Back to results
US 2008/0287480 A1Published application
Therapeutic Combination Comprising a Nmda Receptors Blocker and a Narcotic Analgesic Substance
AssigneeChiesi Farmaceutici S.p.A.
InventorsPaolo Chiesi, Gino Villetti
Life of this patent
Estimating the term…
Abstract
The invention relates to a medicament comprising a combination of a substance that blocks both the ion channel associated to NMDA receptors and MAO enzymes and a narcotic analgesic substance, preferably a fixed combination, pharmaceutical compositions thereof, and to the use thereof for the treatment of subjects suffering of various types of pain and/or for inhibiting the development of tolerance, and/or physical dependence on a narcotic analgesic substance.
Claims14
1:
- A medicament comprising a substance that blocks both the ion channel associated to NMDA receptors and MAO enzymes (a NMDA/MAO blocker) and a narcotic analgesic substance wherein the two substances are administrated simultaneously.
2:
- The medicament according to claim 1 wherein the NMDA/MAO blocker and the narcotic analgesic substance are present in a fixed combination.
3:
- The medicament according to claim 1 wherein the NMDA/MAO blocker is a compound represented by the general formula I:
- wherein:
- R is hydrogen or C1-C4 alkyl groups;
- R1 is hydrogen, C1-C10 alkyl or optionally acylated C1-C4 hydroxyalkyl wherein the acylated C1-C4 hydroxyalkyl is selected from the group of acetyloxy C1-C4 alkyl, propanoyloxy C1-C4 alkyl, 2-methylpropanoyloxy C1-C4 alkyl, and benzoyloxy C1-C4 alkyl;
- R2 is hydrogen;
- C1-C10 alkyl;
- phenyl;
- phenyl C1-C10 alkyl;
- and pharmaceutically acceptable salts thereof.
6 more elements
4:
- The medicament according to claim 3 wherein R, R1 and R2 are hydrogen and the compound is N-2(indanyl)-glycinamide.
5:
- The medicament according to claim 1 wherein the analgesic narcotic substance is selected from the group consisting of fentanyl, hydrocodone, hydromorphone, meperidine, morphine, oxymorphone, phenyltazocine and tramadol, or pharmaceutically acceptable salts thereof such as hydrochloride, sulphate, citrate, lactate and tartrate.
6:
- The medicament according to claim 5 wherein the analgesic narcotic substance is morphine hydrochloride or sulphate.
7:
- A pharmaceutical composition comprising therapeutically effective amounts of a NMDA/MAO blocker and a narcotic analgesic substance, optionally together with at least one pharmaceutically acceptable carrier or diluent.
8:
- A kit comprising:
- a) a therapeutically effective amount of a NMDA/MAO blocker in a pharmaceutically acceptable carrier or diluent in a first unit dosage form;
- b) a therapeutically effective amount of a narcotic analgesic substance or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier or diluent in a second unit dosage form;
- and c) a container for containing said first and second dosage forms in a unique packaging.
1 more element
9:
- A method for the treatment of subjects suffering from moderate to severe pain conditions, acute or chronic, whether the pain is of neuropathic or inflammatory type or caused by different nociceptive stimuli comprising administering simultaneously a combination of a NMDA/MAO blocker and a narcotic analgesic substance.
The method according to claim 9 wherein the combination is a fixed combination.
11:
- The method according to claim 9 wherein the NMDA/MAO blocker is a compound represented by the general formula I:
- wherein:
- R is hydrogen or C1-C4 alkyl groups;
- R1 is hydrogen, C1-C10 alkyl or optionally acylated C1-C4 hydroxyalkyl wherein the acylated C1-C4 hydroxyalkyl is selected from the group of acetyloxy C1-C4 alkyl, propanoyloxy C1-C4 alkyl, 2-methylpropanoyloxy C1-C4 alkyl, and benzoyloxy C1-C4 alkyl;
- R2 is hydrogen;
- C1-C10 alkyl;
- phenyl;
- phenyl C1-C10 alkyl;
- and pharmaceutically acceptable salts thereof.
6 more elements
12:
- The method according to claim 11 wherein R, R1 and R2 are hydrogen and the compound is N-2(indanyl)-glycinamide.
13:
- The method according to claim 9 wherein the pain conditions are mixed pain conditions characterized by the presence of acute and chronic pain components.
14:
- The method according to claim 13 wherein the pain is a neuropathic pain refractory to the treatment with narcotic analgesic substances.
Dependencies are inferred from the claim text.